ATE398287T1 - Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1 - Google Patents

Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1

Info

Publication number
ATE398287T1
ATE398287T1 AT97914488T AT97914488T ATE398287T1 AT E398287 T1 ATE398287 T1 AT E398287T1 AT 97914488 T AT97914488 T AT 97914488T AT 97914488 T AT97914488 T AT 97914488T AT E398287 T1 ATE398287 T1 AT E398287T1
Authority
AT
Austria
Prior art keywords
pp1c
fusion
variant
derivative
compound
Prior art date
Application number
AT97914488T
Other languages
English (en)
Inventor
Philip Cohen
Patricia Cohen
David Barford
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606765.7A external-priority patent/GB9606765D0/en
Priority claimed from GBGB9626362.9A external-priority patent/GB9626362D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE398287T1 publication Critical patent/ATE398287T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT97914488T 1996-03-30 1997-04-01 Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1 ATE398287T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9606765.7A GB9606765D0 (en) 1996-03-30 1996-03-30 Peptides
GBGB9626362.9A GB9626362D0 (en) 1996-12-19 1996-12-19 Peptides

Publications (1)

Publication Number Publication Date
ATE398287T1 true ATE398287T1 (de) 2008-07-15

Family

ID=26309031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914488T ATE398287T1 (de) 1996-03-30 1997-04-01 Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1

Country Status (8)

Country Link
US (1) US6884600B1 (de)
EP (1) EP0891551B1 (de)
JP (1) JP2000508761A (de)
AT (1) ATE398287T1 (de)
AU (1) AU722840B2 (de)
CA (1) CA2250826A1 (de)
DE (1) DE69738761D1 (de)
WO (1) WO1997037224A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159704A (en) * 1996-03-29 2000-12-12 Novartis Ag Phosphatase modulator
DE19805334A1 (de) * 1998-02-11 1999-08-12 Otogene Biotechnologische Fors Verfahren zur Entwicklung eines pharmazeutischen Wirkstoffes
GB9818650D0 (en) 1998-08-27 1998-10-21 Medical Res Council Therapeutic compounds and methods of making and using the same
CA2280276A1 (en) * 1998-09-14 2000-03-14 Pfizer Inc. Assay for detecting modulators of serine/threonine phosphatase activity
GB9820025D0 (en) * 1998-09-14 1998-11-04 Pfizer Ltd Assay
EP1126866B1 (de) * 1998-11-02 2007-02-07 The Regents of The University of California Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
EP1728516A1 (de) * 1998-11-02 2006-12-06 The Regents of the University of California Methode zur Hemmung der Phospholamban Aktivität zur Behandlung von Herzkrankheiten und Herzversagen
ES2320975T3 (es) 2000-09-11 2009-06-01 The Regents Of The University Of California Mutante plb dominante negativo para su utilizacion en el tratamiento de enfermedades cardiacas.
EP1788394B1 (de) * 2002-05-07 2009-06-17 Institut Pasteur Screeningverfahren für PP1-wechselwirkende Polypeptide oder Proteine, Peptide, die die Bindung von PP1c an die Proteine Bcl-2, BCL-XL und BCL-W hemmen, und ihre Verwendung
CN107684828A (zh) * 2017-10-20 2018-02-13 江苏华益科技有限公司 一种高纯氧十六的精馏装置

Also Published As

Publication number Publication date
JP2000508761A (ja) 2000-07-11
US6884600B1 (en) 2005-04-26
AU2172597A (en) 1997-10-22
EP0891551A1 (de) 1999-01-20
AU722840B2 (en) 2000-08-10
CA2250826A1 (en) 1997-10-09
EP0891551B1 (de) 2008-06-11
DE69738761D1 (de) 2008-07-24
WO1997037224A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
DK0914331T3 (da) Neuroaktive peptider
ES2078907T3 (es) Metodo para radiomarcar proteinas.
DE19680255T1 (de) Inhibitoren der Enzymaktivität von Rotamase
NO863596D0 (no) Enbakteriell metionin n-terminal peptidase.
NO911963D0 (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
DE69833948D1 (de) Aktives system zur frühen zerstörung von schleppwirbeln
BR9407583A (pt) Processos para produzir uma proteina bcl-2 mutante para identificar agentes modulantes de bcl-2 candidatos um bcl-2 mutante e proteinas bcl-2 mutantes e para inibir a atividade repressora de morte de células de bcl-2 e polipeptideo bcl-2 mutante
IT8320064A0 (it) Inibitori dell'enzima che trasforma l'angiotensina, costituiti da acidi amminoalchilfosfinici e da acidi amminofosfinici sostituiti simili.
DE60020146D1 (de) Two-hybrid-Screeningverfahren unter Verwendung des bakteriellen Transcriptionsaktivators sigma-54
ATE398287T1 (de) Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1
DK1025227T3 (da) Humane TOLL-homologer
NO166303C (no) Fremgangsmaate ved kvantitativ bestemmelse av protein c ogaktivatorpreparat til gjennomfoering av fremgangsmaaten.
ATE375399T1 (de) Isolierung von gewebspezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane
PT864559E (pt) Compostos amino substituidos e sua utilizacao como substancias activas analgesicas
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
DE3676601D1 (de) Mittel zur injektion von aktiviertem vitamin-d3.
TR199802394A3 (tr) Proteinleri stabilize etmek için gelistirilmis proses.
PT1036323E (pt) Sistema multi-hibrido bacteriano e aplicacoes
WO2001044497A3 (en) Protein kinase regulation
EP1009853A4 (de) Assays zur detektierung von modulatoren der cytoskeletalen funktion
WO2002048403A3 (en) Multiplexed protein expression and activity assay
ATE284955T1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
DE69803700D1 (de) Zusammensetzung auf basis von frischkäse
DE59604894D1 (de) Testsystem zur erfassung der aktivität von nk-zellen
WO1998020124A3 (en) Diabetes-mediating proteins and therapeutic uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties